EN DE

Skylight Health Group (SLHGF) Fair Value & Analysis

Healthcare · US · Market cap $4.0K

SH Skylight Health Group logo Skylight Health Group SLHGF · US
Price$0.0001
Fair Value$0.0001
Upside+0.0%
Quality37/100
Watch Skylight Health Group for free, get notified when fair value or trend changes. Watch for free
Mixed Growth
Loss-making · -37.8% net margin
negative free cash flow
Trails peers (2/7)
Narrow moat 6/100
Evidence: Low Range $0.0001 – $0.0001 Share as image

Fair value as of: Jul 31, 2026

From 1 valuation models · updated 10 days ago

Below-average quality, currently priced close to our fair value.

What matters now

  • The price sits close to our fair value, market and models broadly agree here, little valuation tension.
  • Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.
Share this valuation: 𝕏 WhatsApp

Price vs Fair Value (5 years)

$6.60 $0.0001 Fair Value $0.0001 Apr 2021 Jul 2026

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 31, 2026.

How to read this chart

60‑month range $0.0001 – $6.60 · the $0.0001 price screens below the $0.0001 fair value. Dashed = 300-day average. As of Jul 31, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Skylight Health Group (SLHGF) currently trades at $0.0001, while our model-based Fair Value estimate is $0.0001, implying the stock looks roughly 0.0% fairly valued today. The Quality Score stands at 37/100 (below-average quality), in the Healthcare sector. Bull case: trading below our estimate, it may offer upside if the fundamentals hold. Bear case: a low price can be a value trap when quality is weak or the data is thin (evidence: low), always confirm before acting.

Over the trailing twelve months, Skylight Health Group generated revenue of $54.0M at a net margin of -37.8%. Revenue grew 139.7% year over year. It earns a return on equity of -96.9%. Net debt stands at $4.5M. Fundamentals as of Jul 31, 2026

The share trades near its 52-week high, currently above its 200-day average. For context, the median of 10 Healthcare peers we cover trades at 11% fair-value upside, at 0%, SLHGF screens richer than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Model Bear Bear = the cautious scenario: the same model computed with conservative anchors (lower growth, margins and valuation multiples). Together with Bull it frames a plausible valuation range, not a price target.BaseBull Bull = the optimistic scenario: the same model computed with favourable anchors (higher growth, margins and valuation multiples). Together with Bear it frames a plausible valuation range, not a price target. Evidence
Highest evidence
NCAV (Graham) $0.0001 $0.0001 $0.0001 50
All 1 models by family
Asset-Based
NCAV (Graham) $0.0001 $0.0001 $0.0001 50

Notify me when SLHGF reaches fair value

Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.

Key figures & financial health

Revenue (TTM) $54.0M
Revenue growth (YoY) +140%
Net margin -37.8%
Return on equity -96.9%
Free cash flow −$11.7M FY2021
Operating margin -26.9%
More key figures
EPS (TTM) $-5.00
Net debt $4.5M FY2021

Figures from reported company fundamentals · as of Jul 31, 2026. TTM = trailing twelve months.

Quality Score breakdown

Overall quality 37/100

Of which business quality 41 · Market factors (momentum, volatility) 66

Profitability 13
Margins and returns on capital today
Quality Growth 100
Are margins and returns improving?
Cashflow 30
Earnings quality: real cash, not paper profit
Fin. Strength 62
Balance sheet, leverage, solvency risk
Investment 50
Disciplined investing over empire-building
Low Volatility 100
Calm price path (market factor)
Momentum 44
Price trend over the last 3–12 months (market factor)
Net Issuance 0
Buybacks instead of dilution

Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.

About the company

Skylight Health Group Inc. operates as a healthcare services and technology company in the United States. The company operates the US multi-state primary care health network, which provides a range of services from primary and urgent care, sub-specialty, allied health and wellness, and laboratory/diagnostic testing.

Full company description

Skylight Health Group Inc. operates as a healthcare services and technology company in the United States. The company operates the US multi-state primary care health network, which provides a range of services from primary and urgent care, sub-specialty, allied health and wellness, and laboratory/diagnostic testing. It also provides healthcare services for older and disabled patients. The company was formerly known as CB2 Insights Inc. and changed its name to Skylight Health Group Inc. in November 2020. Skylight Health Group Inc. was founded in 2014 and is headquartered in Mississauga, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2017 – FY2021 · reported fiscal years

Skylight Health Group reported revenue of $27.2M in FY2021 versus $280K in FY2017, a compound +213.8%/yr. Reported net income was −$13.7M in FY2021.

Growth Quality 34/100
Revenue is growing, but margins or cash flow do not fully confirm the trend.
Latest Revenue (FY 2021)
$27.2M
Avg. growth/yr (5Y) Measures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump.
+610.5%
Revenue +213.8%/yr
FY17 $280K
FY18 $0
FY19 $13.4M
FY20 $689K
FY21 $27.2M
Net income
FY17 −$1.3M
FY18 −$218K
FY19 −$11.0M
FY20 −$9.5M
FY21 −$13.7M

Watch SLHGF: get an alert when its fair value changes →

Share or link this analysis
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

Cite: Fair Value Calculator (2026). "Skylight Health Group Fair Value". https://www.fairvalue-calculator.com/stock/SLHGF

Peer Group

Medical Care Facilities · 261 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Quality Score 37 · Bottom 25%
Fair Value upside +0% · Above median
Return on assets -24% · Bottom 25%
Net margin (TTM) -38% · Bottom 25%
Operating margin (TTM) -27% · Bottom 25%
Revenue growth 140% · Top 25%

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 33 · sector 23
FUTURE 100 · sector 24
PAST 0 · sector 30
HEALTH 0 · sector 90
DIVIDEND 0 · sector 38

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Medical Care Facilities stocks, each showing price versus our Fair Value estimate (as of Jul 31, 2026).

Stock Price Fair Value vs Fair Value
HCA Healthcare, Inc HCA $378.85 $554.93 +46%
Fresenius SE FRE €41.73 €32.15 -23%
Dr. Sulaiman Al Habib Medical Services Group 4013 235.00 SAR 112.37 SAR -52%
IHH Healthcare Berhad, an investment holding company, Q0F 2.58 SGD 1.44 SGD -44%
Tenet Healthcare Corporation THC $194.91 $338.05 +73%
Rede D'Or São Luiz S.A RDOR3 R$36.01 R$47.31 +31%
DaVita Inc DVA $231.61 $255.97 +11%
Apollo Hospitals Enterprise Limited APOLLOHOSP ₹8,955 ₹2,955 -67%
Fresenius Medical Care AG FMS $24.68 $45.60 +85%
Aier Eye Hospital Group 300015 ¥8.68 ¥7.67 -12%

Compare Skylight Health Group with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend Stocks

Frequently asked questions

Is Skylight Health Group (SLHGF) overvalued or undervalued?
As of Jul 31, 2026, our model estimates a fair value of $0.0001 versus a price of $0.0001, about +0% (fairly valued).
What is the fair value of SLHGF?
Our model-based fair value for Skylight Health Group is $0.0001 (as of Jul 31, 2026), built from audited fundamentals. The current price is $0.0001.
What is the quality score of SLHGF?
Skylight Health Group has a Quality Score of 37/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the revenue of Skylight Health Group (SLHGF)?
Skylight Health Group reported trailing-twelve-month revenue of about $54.0M (latest available figure, as of Jul 31, 2026).
What is the net profit margin of SLHGF?
The net profit margin of Skylight Health Group is about -37.8%, meaning it is currently running at a net loss. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.

14 days Pro free · no card

Track Skylight Health Group and try Pro for 14 days

One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.

Zero risk: nothing is ever charged. After 14 days you decide whether to stay.